Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
CNTY-101 · 1 trial · 4 indications
| Arm | Type | Description |
|---|---|---|
| Arm A: CNTY-101 in SLE Participants | EXPERIMENTAL | During Part 1 (Dose Confirmation Phase), participants with SLE will undergo lymphodepleting chemotherapy (LDC) followed by administration of CNTY-101, administered 3 times over 3 weeks, during Cycle 1 (cycle length = 28 days), alone or with supplemental human recombinant interleukin 2 (IL-2). After completion of Cycle 1, CNTY-101 (without preceding LDC), will be administered 3 times over 3 weeks, during Cycle 2 (cycle length = 28 days), alone or with supplemental IL-2. During Part 2 (Dose Expansion Phase), participants will receive treatments using the recommended phase 2 regimen (RP2R) confirmed during Part 1. |
| Arm B: CNTY-101 in LN Participants | EXPERIMENTAL | During Part 1 (Dose Confirmation Phase), participants with LN will undergo LDC followed by administration of CNTY-101, administered 3 times over 3 weeks, during Cycle 1 (cycle length = 28 days), alone or with supplemental IL-2. After completion of Cycle 1, CNTY-101 (without preceding LDC), will be administered 3 times over 3 weeks, during Cycle 2 (cycle length = 28 days), alone or with supplemental IL-2. During Part 2 (Dose Expansion Phase), participants will receive treatments using the RP2R confirmed during Part 1. |
| Arm C: CNTY-101 in IIM Participants | EXPERIMENTAL | During Part 1 (Dose Confirmation Phase), participants with IIM will undergo LDC followed by administration of CNTY-101, administered 3 times over 3 weeks, during Cycle 1 (cycle length = 28 days), alone or with supplemental IL-2. After completion of Cycle 1, CNTY-101 (without preceding LDC), will be administered 3 times over 3 weeks, during Cycle 2 (cycle length = 28 days), alone or with supplemental IL-2. During Part 2 (Dose Expansion Phase), participants will receive treatments using the RP2R confirmed during Part 1. |
| Arm D: CNTY-101 in DcSSC Participants | EXPERIMENTAL | During Part 1 (Dose Confirmation Phase), participants with DcSSC will undergo LDC followed by administration of CNTY-101, administered 3 times over 3 weeks, during Cycle 1 (cycle length = 28 days), alone or with supplemental IL-2. After completion of Cycle 1, CNTY-101 (without preceding LDC), will be administered 3 times over 3 weeks, during Cycle 2 (cycle length = 28 days), alone or with supplemental IL-2. During Part 2 (Dose Expansion Phase), participants will receive treatments using the RP2R confirmed during Part 1. |
| Name | Type | Description |
|---|---|---|
| CNTY-101 | BIOLOGICAL | CNTY-101 cells for intravenous (IV) infusion |
| IL-2 | BIOLOGICAL | IL-2 subcutaneous (SC) injection |
| Lymphodepleting Chemotherapy | DRUG | LDC as prespecified in the protocol. |
Inclusion Criteria: General Inclusion Criteria: 1. 17 years of age and older. 2. Participants must have adequate organ function as defined in the protocol. SLE/LN-specific Inclusion Criteria: 1. Participants must have a diagnosis of SLE according to the 2019 European League Against Rheumatism/Am...
Top 20 of 32 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Biogen Inc. | BIIB | 5 | PHASE3 | Litifilimab |
| Bristol-Myers Squibb Company | BMY | 7 | PHASE3 | Deucravacitinib |
| Viatris, Inc. | VTRS | 5 | PHASE3 | Cenerimod |
| Novartis AG Sponsored ADR | NVS | 7 | PHASE3 | Ianalumab |
| AstraZeneca PLC | AZN | 21 | PHASE3 | Medi-546 |
| Johnson & Johnson | JNJ | 1 | PHASE3 | Nipocalimab |
| AbbVie, Inc. | ABBV | 2 | PHASE3 | Upadacitinib |
| GSK plc Sponsored ADR | GSK | 3 | PHASE2 | Belimumab |
| Sanofi SA Sponsored ADR | SNY | 2 | PHASE2 | SAR441344 |
| Zenas BioPharma, Inc. | ZBIO | 1 | PHASE2 | Obexelimab |
| Alumis Inc. | ALMS | 1 | PHASE2 | Envudeucitinib |
| Immunovant Inc | IMVT | 1 | PHASE2 | IMVT-1402 |
| Amgen Inc. | AMGN | 1 | PHASE2 | Inebilizumab, Blinatumomab |
| Fate Therapeutics, Inc. | FATE | 2 | PHASE2 | FT819 |
| Eli Lilly and Company | LLY | 1 | PHASE1 | LY4298445 |
| Cartesian Therapeutics, Inc. | RNAC | 2 | PHASE2 | Descartes-08 |
| Merck & Co., Inc. | MRK | 1 | PHASE1 | MK-1045 |
| Gilead Sciences, Inc. | GILD | 1 | PHASE1 | KITE-363, Fludarabine, Cyclophosphamide |
| Artiva Biotherapeutics, Inc. | ARTV | 2 | PHASE1 | AB-101, Cyclophosphamide, Fludarabine, Rituximab, Obinutuzumab |
| Cullinan Therapeutics, Inc. | CGEM | 1 | PHASE1 | CLN-978 |
CNTY-101 is an investigational monoclonal antibody being developed for the treatment of Systemic Lupus Erythematosus (SLE). It is currently in Phase 1 clinical development and is being studied in patients with refractory B cell-mediated autoimmune diseases, including SLE and lupus nephritis.
CNTY-101 targets CD19, an antigen expressed on B cells. By targeting CD19, the drug is designed to modulate B cell activity, which is relevant to autoimmune conditions like Systemic Lupus Erythematosus where B cells play a pathogenic role.
CNTY-101 is being developed by Century Therapeutics, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol IPSC. The company is conducting clinical trials to evaluate the drug's safety and efficacy in autoimmune diseases.
CNTY-101 is in Phase 1 clinical development. It is an investigational drug, meaning it has not yet been approved by regulatory authorities. The ongoing Phase 1 trial is actively enrolling participants to assess the drug in refractory B cell-mediated autoimmune diseases.
CNTY-101 is being evaluated in a Phase 1 clinical trial registered as NCT06255028, titled "A Study of CNTY-101 in Participants With Refractory B Cell-mediated Autoimmune Diseases." The trial is active but not recruiting, with an enrollment of 6 participants, and is being conducted in the United States.
No alternative names for CNTY-101 have been reported. It is a distinct investigational monoclonal antibody developed by Century Therapeutics, Inc., and is not known to be marketed under any other name.